Drug intelligence / Profile preview

GSK1322888

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

GSK1322888 is a potent and selective small molecule motilin receptor agonist developed by GSK. It was investigated primarily for the treatment of gastroparesis, a condition characterized by delayed gastric emptying. The drug acts as an agonist at the motilin receptor, which plays a key role in stimulating gastrointestinal motility. Clinical studies have focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers[1][3][4][7].

Other names: 1322888

Targets

MLNR (Human motilin receptor)

Beyond the preview

Go deeper on GSK1322888.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK1322888.

Explore the full profile